Clinical Edge Journal Scan

Meta-analysis shows MRI as most effective supplemental BC screening tool


 

Key clinical point: Magnetic resonance imaging (MRI) proved to be the best supplemental breast cancer (BC) screening modality in women with dense breasts and who had a negative mammogram who were at an average or intermediate risk for the disease.

Major finding: Among the screened patients with dense breasts and a negative mammogram, 541 cases of BC were detected using supplemental modalities. The incremental cancer detection rate was highest with MRI (1.54 per 1,000 screenings) compared with other supplemental modalities ( P < .001).

Study details: Findings are from a meta-analysis of 22 randomized clinical trials and prospective observational studies including 261,233 patients, of which 120,081 patients had dense breasts and a negative mammogram.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Hussein H et al. Supplemental breast cancer screening in women with dense breasts and negative mammography: A systematic review and meta-analysis. Radiology. 2023;221785 (Jan 31). Doi: 10.1148/radiol.221785

Recommended Reading

Real-world survival benefit with CDK4/6 inhibitors in MBC
MDedge Hematology and Oncology
Postoperative accelerated partial breast irradiation noninferior to whole breast irradiation in early BC
MDedge Hematology and Oncology
Neoadjuvant chemotherapy with nab-paclitaxel+pembrolizumab shows encouraging pCR rates in TNBC
MDedge Hematology and Oncology
Neoadjuvant ET: A reasonable standard-of-care in stage II/III ER+ BC
MDedge Hematology and Oncology
Trastuzumab improves survival in a real-world HER2+ early BC population
MDedge Hematology and Oncology
HER2+ metastatic BC brain metastases: Superior survival outcomes with trastuzumab emtansine vs lapatinib+capecitabine
MDedge Hematology and Oncology
Anti-HER2 therapy may be omitted in patients with HER2+ ILC
MDedge Hematology and Oncology
HER2+/HR+ metastatic BC: Adding pertuzumab to trastuzumab+AI shows PFS benefit
MDedge Hematology and Oncology
Meta-analysis associates HER2-low expression with good prognosis in early BC
MDedge Hematology and Oncology
ET duration: A risk factor for cognitive impairment in BC patients
MDedge Hematology and Oncology